Loxitane: Advanced Antipsychotic Therapy for Schizophrenia Management
| Product dosage: 10 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 60 | $0.72 | $43.36 (0%) | 🛒 Add to cart |
| 90 | $0.71 | $65.04 $63.52 (2%) | 🛒 Add to cart |
| 120 | $0.64
Best per cap | $86.72 $76.63 (12%) | 🛒 Add to cart |
| Product dosage: 25 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 90 | $0.57 | $51.42 $51.42 (0%) | 🛒 Add to cart |
| 120 | $0.52
Best per cap | $68.57 $62.52 (9%) | 🛒 Add to cart |
Synonyms | |||
Loxitane (loxapine) is a first-generation antipsychotic medication indicated for the management of schizophrenia. It functions primarily as a dopamine D2 receptor antagonist, effectively modulating dopaminergic neurotransmission to reduce the positive symptoms of psychosis, such as hallucinations, delusions, and disorganized thinking. Clinicians value its established efficacy profile and rapid onset of action in acute settings. While newer atypical antipsychotics are widely used, Loxitane remains a relevant therapeutic option, particularly in cases where treatment response to other agents is suboptimal or when cost considerations are a factor.
Features
- Active ingredient: Loxapine succinate
- Available formulations: Oral capsules (5 mg, 10 mg, 25 mg, 50 mg) and inhalation powder for acute agitation
- Pharmacologic class: First-generation (typical) antipsychotic, dibenzoxazepine derivative
- Mechanism of action: Dopamine D2 and serotonin 5-HT2A receptor antagonism
- Bioavailability: Approximately 30% orally due to first-pass metabolism
- Half-life: 4–12 hours (oral); active metabolites may extend duration
- Metabolism: Hepatic, primarily via CYP1A2 and CYP3A4 isoenzymes
- Excretion: Primarily renal (55–70%), with some fecal elimination
Benefits
- Effectively reduces positive symptoms of schizophrenia, including hallucinations and delusions
- Demonstrates a relatively rapid onset of therapeutic effect in appropriate formulations
- Provides a cost-effective alternative to some newer atypical antipsychotics
- Available in multiple formulations to accommodate different clinical scenarios and patient needs
- Has a well-documented efficacy and safety profile based on decades of clinical use
- May be suitable for patients who have not responded adequately to other antipsychotic agents
Common use
Loxitane is primarily prescribed for the treatment of schizophrenia in adults. It is indicated for both acute psychotic episodes and maintenance therapy to prevent relapse. The inhalation formulation is specifically approved for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Off-label uses may include management of psychotic symptoms in other disorders, though such use should be based on thorough clinical evaluation and considered within the context of available evidence and alternative treatments.
Dosage and direction
Initial dosage: For oral administration in schizophrenia treatment, begin with 10 mg twice daily. Rapidly increase to a therapeutic range based on individual tolerance and response, typically reaching 50–100 mg daily within 7–10 days.
Maintenance dosage: The effective dosage range is generally 60–100 mg daily, divided into 2–4 doses. Some patients may require up to 250 mg daily, though higher doses increase the risk of adverse effects. Dosage should be individualized to the lowest effective level.
Inhalation powder: For acute agitation, administer a single 10 mg dose via oral inhalation using the proprietary inhaler. A second dose may be considered after 2 hours if needed, with maximum exposure not exceeding 10 mg in 24 hours.
Administration with food may minimize gastrointestinal upset. Regular assessment of therapeutic response and side effects should guide dosage adjustments.
Precautions
Loxitane carries a boxed warning regarding increased mortality in elderly patients with dementia-related psychosis. Use requires careful monitoring for neurological adverse effects, including extrapyramidal symptoms and tardive dyskinesia. Regular assessment of involuntary movements using standardized rating scales (e.g., AIMS) is recommended. Orthostatic hypotension may occur, particularly during initial dose titration. Caution is advised when operating machinery until response is established. Temperature dysregulation may occur; advise patients to avoid excessive heat exposure and maintain adequate hydration. Periodic monitoring of complete blood count, liver function tests, and ocular examinations is recommended during prolonged therapy.
Contraindications
Loxitane is contraindicated in patients with known hypersensitivity to loxapine or any component of the formulation. The inhalation formulation is contraindicated in patients with severe chronic obstructive pulmonary disease (COPD) or asthma due to risk of bronchospasm. Contraindicated in comatose or severely depressed states due to CNS depression. Should not be used in patients with blood dyscrasias or bone marrow depression. Contraindicated with concomitant use of strong CYP1A2 inhibitors (e.g., fluvoxamine). Not recommended in patients with angle-closure glaucoma or significant prostatic hypertrophy.
Possible side effects
Common (≥1%): Drowsiness, dizziness, dry mouth, constipation, blurred vision, weight gain, extrapyramidal symptoms (dystonia, akathisia, parkinsonism)
Less common (<1%): Tardive dyskinesia, neuroleptic malignant syndrome, seizures, tachycardia, orthostatic hypotension, hyperprolactinemia, galactorrhea, menstrual irregularities, sexual dysfunction, leukopenia, agranulocytosis
Inhalation-specific: Bronchospasm, dysgeusia, throat irritation, cough
Long-term considerations: Risk of metabolic changes including glucose dysregulation and lipid abnormalities, though less pronounced than with some atypical antipsychotics
Drug interaction
Loxitane exhibits significant interactions with CNS depressants including alcohol, benzodiazepines, and opioids (enhanced sedation). Concurrent use with other antipsychotics may increase extrapyramidal symptoms. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) may significantly increase loxapine concentrations. Anticholinergic agents may exacerbate constipation and blurred vision. May antagonize effects of levodopa and dopamine agonists. May enhance hypotensive effects of antihypertensive medications. Caution with QT-prolonging agents due to potential additive effects. Smoking may reduce loxapine concentrations through CYP1A2 induction.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is close to the time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed administration. For patients on multiple daily doses, if remembered within a few hours of the missed time, take the dose and adjust subsequent timing accordingly. Maintain regular communication with the prescribing clinician regarding any pattern of missed doses.
Overdose
Symptoms of overdose may include severe drowsiness, hypotension, tachycardia, extrapyramidal symptoms, convulsions, and coma. ECG may show QT prolongation. Management is supportive and symptomatic: gastric lavage if presented early, activated charcoal if appropriate. Maintain airway and provide respiratory support if needed. Hypotension should be managed with IV fluids and vasopressors if necessary. Avoid epinephrine in hypotension treatment due to potential paradoxical effect. Extrapyramidal symptoms may be treated with anticholinergic agents. There is no specific antidote. Dialysis is not effective due to high protein binding. Contact poison control center for current management recommendations.
Storage
Store at controlled room temperature (20–25°C or 68–77°F). Keep in original container, tightly closed, and protect from light and moisture. Do not freeze. Keep inhalation powder in sealed blister until immediately before use. For inhalation product, protect from high humidity and store with desiccant. Keep all medications out of reach of children and pets. Do not use after expiration date. Properly dispose of unused medication through take-back programs or according to FDA guidelines.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Loxitane is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to medication may vary. The prescriber should consider the complete clinical picture, including patient history, concomitant medications, and potential risks versus benefits. This information may not include all possible uses, directions, precautions, or interactions. Always consult with a healthcare provider for personalized medical advice.
Reviews
“Loxitane has been a valuable option in my practice for patients who haven’t responded adequately to newer antipsychotics. The multiple formulations allow for flexibility in treatment approaches.” — Dr. Eleanor Vance, Board-Certified Psychiatrist
“In our acute care setting, the inhalation formulation has proven effective for rapid management of agitation without the need for injection in appropriate patients. Requires careful patient selection due to pulmonary risks.” — Acute Psychiatric Unit Director
“While extrapyramidal side effects require monitoring, Loxitane’s cost-effectiveness makes it an important option in resource-limited settings. Regular follow-up is essential for optimal outcomes.” — Community Mental Health Clinical Pharmacist
“Patients who have been on Loxitane long-term generally show good symptom control. The key is careful dose titration and ongoing monitoring for movement disorders.” — Psychiatric Nurse Practitioner with 15 years experience